| Q64100367 | Q64100367 |
| Q47669638 | A Case of IgA Nephropathy after Nivolumab Therapy for Postoperative Recurrence of Lung Squamous Cell Carcinoma. |
| Q92061847 | A Case of Isolated Adrenocorticotropic Hormone Deficiency Caused by Pembrolizumab |
| Q90292730 | A Case of Nivolumab-Induced Bullous Pemphigoid: Review of Dermatologic Toxicity Associated with Programmed Cell Death Protein-1/Programmed Death Ligand-1 Inhibitors and Recommendations for Diagnosis and Management |
| Q48154177 | A Comprehensive Review of US FDA-Approved Immune Checkpoint Inhibitors in Urothelial Carcinoma |
| Q51417665 | A Rare Case of Pembrolizumab-Induced Uveitis in a Patient with Metastatic Melanoma. |
| Q47919269 | A Review of Immune Checkpoint Inhibitors for the Management of Locally Advanced or Metastatic Urothelial Carcinoma. |
| Q92433740 | A case of cystitis after administration of nivolumab |
| Q99566061 | A case of large-cell lung carcinoma successfully treated with pembrolizumab but complicated with cholangitis |
| Q93080047 | A nanoparticle-incorporated STING activator enhances antitumor immunity in PD-L1-insensitive models of triple-negative breast cancer |
| Q90115488 | A new immune signature for survival prediction and immune checkpoint molecules in lung adenocarcinoma |
| Q60931655 | A severe case of refractory esophageal stenosis induced by nivolumab and responding to tocilizumab therapy |
| Q48517891 | Activity of pembrolizumab in relapsed/refractory NK/T-cell lymphoma |
| Q90665031 | Acute tubulointerstitial nephritis and IgM deposits on glomerular capillary walls after immunotherapy with nivolumab for metastatic renal cell carcinoma |
| Q28080113 | Advances in Cancer Immunotherapy in Solid Tumors |
| Q55411796 | Advances in the Use of Immunotherapy in Oncology. |
| Q46884498 | Adverse Events in Cancer Immunotherapy |
| Q91689845 | Aging, Cancer and Immunity |
| Q92349905 | Autoimmune Endocrine Dysfunctions Associated with Cancer Immunotherapies |
| Q50057565 | Autoimmune reactions to immune checkpoint inhibitors |
| Q52615452 | Baseline antibody profiles predict toxicity in melanoma patients treated with immune checkpoint inhibitors. |
| Q51655915 | Battling regional (stage III) lung cancer: bumpy road of a cancer survivor in the immunotherapy age. |
| Q40044531 | Bile duct obstruction in a patient treated with nivolumab as second-line chemotherapy for advanced non-small-cell lung cancer: a case report |
| Q56893015 | Bispecific antibodies in cancer immunotherapy |
| Q49315568 | Breakthroughs in modern cancer therapy and elusive cardiotoxicity: Critical research-practice gaps, challenges, and insights |
| Q41064873 | Cancer Immunotherapy, Part 2: Efficacy, Safety, and Other Clinical Considerations |
| Q56891117 | Cancer immune checkpoint blockade therapy and its associated autoimmune cardiotoxicity |
| Q37737940 | Cancer immunotherapies targeting the PD-1 signaling pathway |
| Q89972510 | Cancer patients' experiences with immune checkpoint modulators: A qualitative study |
| Q61811027 | Cardiac Complications in Immune Checkpoint Inhibition Therapy |
| Q48109228 | Cardio-Oncology: mechanisms of cardiovascular toxicity. |
| Q52592605 | Cardiotoxicity of Immunotherapy: Incidence, Diagnosis, and Management. |
| Q42374962 | Checkpoint Inhibitor-Induced Colitis: A New Type of Inflammatory Bowel Disease? |
| Q90238061 | Chemoradiotherapy followed by durvalumab in patients with unresectable advanced non-small cell lung cancer: Management of adverse events |
| Q91843400 | Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse Study |
| Q55292659 | Clinical assessment of immune-related adverse events. |
| Q57029319 | Clinical implications of monitoring nivolumab immunokinetics in non-small cell lung cancer patients |
| Q48007461 | Coincidence of immunotherapy-associated hemophagocytic syndrome and rapid tumor regression |
| Q53723979 | Colon Immune-Related Adverse Events: Anti-CTLA-4 and Anti-PD-1 Blockade Induce Distinct Immunopathological Entities. |
| Q90743227 | Combination immunotherapy with anti-PD-L1 antibody and depletion of regulatory T cells during acute viral infections results in improved virus control but lethal immunopathology |
| Q93255446 | Combination therapy for metastatic melanoma: a pharmacist's role, drug interactions & complementary alternative therapies |
| Q37708989 | Combining a GSI and BCL-2 inhibitor to overcome melanoma's resistance to current treatments |
| Q47727627 | Comparison of the toxicity profile of PD-1 versus PD-L1 inhibitors in non-small cell lung cancer: A systematic analysis of the literature |
| Q92152744 | Cumulative Toxicity in Targeted Therapies: What to Expect at the Recommended Phase II Dose |
| Q38848990 | Current and future immunotherapeutic approaches in Hodgkin lymphoma |
| Q47781457 | Current and future immunotherapies for thyroid cancer |
| Q54574397 | Current status and perspectives in immunotherapy for metastatic melanoma. |
| Q59350349 | Current status of immunotherapy in metastatic colorectal cancer |
| Q91247787 | Deep phenotyping of immune cell populations by optimized and standardized flow cytometry analyses |
| Q91590737 | Delayed immune-related events (DIRE) after discontinuation of immunotherapy: diagnostic hazard of autoimmunity at a distance |
| Q47277879 | Dermatologic Reactions to Immune Checkpoint Inhibitors : Skin Toxicities and Immunotherapy. |
| Q91639427 | Downregulation of PD-L1 via amide analogues of brefelamide: Alternatives to antibody-based cancer immunotherapy |
| Q57034228 | Efficacy of anti-PD-1/PD-L1 antibodies after discontinuation due to adverse events in non-small cell lung cancer patients (HANSHIN 0316) |
| Q47956257 | Emerging immunotherapy in advanced renal cell carcinoma |
| Q90680382 | Employing Parasite Against Cancer: A Lesson From the Canine Tapeworm Echinococcus Granulocus |
| Q90612109 | Endocrine adverse events related to immune-oncology agents: retrospective experience of a single institution |
| Q58591401 | French Endocrine Society Guidance on endocrine side-effects of immunotherapy |
| Q37642460 | From targeting the tumor to targeting the immune system: Transversal challenges in oncology with the inhibition of the PD-1/PD-L1 axis. |
| Q38971262 | Genomic Approaches to Understanding Response and Resistance to Immunotherapy |
| Q90350661 | Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study |
| Q64085283 | Hematological Side Effects of Immune Checkpoint Inhibitors: The Example of Immune-Related Thrombocytopenia |
| Q55252709 | Hemophagocytic lymphohistiocytosis with immunotherapy: brief review and case report. |
| Q64885788 | Immune Checkpoint Blockade for Advanced NSCLC: A New Landscape for Elderly Patients. |
| Q92069778 | Immune Checkpoint Inhibitor-Associated Cardiotoxicity: Current Understanding on Its Mechanism, Diagnosis and Management |
| Q39328076 | Immune Checkpoint Inhibitor-Induced Colitis: Diagnosis and Management |
| Q38800974 | Immune checkpoint inhibition in ovarian cancer |
| Q42356272 | Immune checkpoint inhibitor-associated interstitial lung diseases: some progress but still many issues |
| Q47633085 | Immune checkpoint inhibitor-related myocarditis |
| Q92460057 | Immune checkpoint inhibitors and tuberculosis: an old disease in a new context |
| Q55426703 | Immune checkpoint inhibitors in urothelial cancer: recent updates and future outlook. |
| Q39430042 | Immune checkpoint inhibitors: Navigating a new paradigm of treatment toxicities |
| Q90257606 | Immune-Related Adverse Events in the Setting of PD-1/L1 Inhibitor Combination Therapy |
| Q59126189 | Immune-related adverse events of immune checkpoint inhibitors: a brief review |
| Q55284597 | Immune-related adverse events with immune checkpoint inhibitors in thoracic malignancies: focusing on non-small cell lung cancer patients. |
| Q39044147 | Immuno-Oncology: The Third Paradigm in Early Drug Development |
| Q92616105 | Immunological Agents Used in Cancer Treatment |
| Q64061325 | Immunotherapy Associated Pulmonary Toxicity: Biology Behind Clinical and Radiological Features |
| Q90220124 | Immunotherapy for Non-small Cell Lung Cancer: Current Landscape and Future Perspectives |
| Q33819820 | Immunotherapy for Patients with Advanced Urothelial Cancer: Current Evidence and Future Perspectives. |
| Q38629357 | Immunotherapy in Breast Cancer: the Emerging Role of PD-1 and PD-L1. |
| Q88012969 | Implementing Keytruda/Pembrolizumab Testing in Clinical Practice |
| Q55438940 | Incidence of immune checkpoint inhibitor-related colitis in solid tumor patients: A systematic review and meta-analysis. |
| Q47608535 | Inflammatory gastrointestinal diseases associated with PD-1 blockade antibodies |
| Q38893697 | Ipilimumab in melanoma |
| Q42070314 | Long-term Response to Nivolumab and Acute Renal Failure in a Patient with Metastatic Papillary Renal Cell Carcinoma and a PD-L1 Tumor Expression Increased with Sunitinib Therapy: A Case Report |
| Q91938480 | Management of Adverse Events in Cancer Patients Treated With PD-1/PD-L1 Blockade: Focus on Asian Populations |
| Q50015039 | Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. |
| Q50205173 | Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up |
| Q94225733 | Managing Side Effects of Cancer Patients Treated With Immunotherapy |
| Q56890058 | Metformin Promotes Antitumor Immunity via Endoplasmic-Reticulum-Associated Degradation of PD-L1 |
| Q92101803 | Moderate-to-severe eosinophilia induced by treatment with immune checkpoint inhibitors: 37 cases from a national reference center for hypereosinophilic syndromes and the French pharmacovigilance database |
| Q48306002 | Modulating Tumor Immunology by Inhibiting Indoleamine 2,3-Dioxygenase (IDO): Recent Developments and First Clinical Experiences. |
| Q38930084 | Monitoring and Management of Immune-Related Adverse Events Associated With Programmed Cell Death Protein-1 Axis Inhibitors in Lung Cancer |
| Q94475386 | Nephrotoxicity in cancer treatment: An overview |
| Q57172529 | Nephrotoxicity of Cancer Immunotherapies: Past, Present and Future |
| Q47625145 | Neuro-ophthalmic side effects of molecularly targeted cancer drugs |
| Q40204803 | Neurologic Serious Adverse Events Associated with Nivolumab Plus Ipilimumab or Nivolumab Alone in Advanced Melanoma, Including a Case Series of Encephalitis. |
| Q47649537 | Neuromyelitis optica spectrum disorder secondary to treatment with anti-PD-1 antibody nivolumab: the first report |
| Q52653710 | Next generation of immune checkpoint therapy in cancer: new developments and challenges. |
| Q36201404 | Nivolumab-associated acute glomerulonephritis: a case report and literature review. |
| Q95282151 | Oncologic Emergencies: Immune-Based Cancer Therapies and Complications |
| Q87997894 | Optimal management of immune-related adverse events resulting from treatment with immune checkpoint inhibitors: a review and update |
| Q39185692 | Otorhinolaryngological Toxicities of New Drugs in Oncology |
| Q58701610 | Overall survival of stage IV non-small cell lung cancer patients treated with Viscum album L. in addition to chemotherapy, a real-world observational multicenter analysis |
| Q26768641 | PD-1/PD-L1 blockade in cancer treatment: perspectives and issues |
| Q48114756 | PD1 blockade with low-dose nivolumab in NK/T cell lymphoma failing L-asparaginase: efficacy and safety |
| Q57073426 | PD1/PDL1 inhibitors for the treatment of advanced urothelial bladder cancer |
| Q58707974 | Pan-cancer analysis of neoepitopes |
| Q91828693 | Pancytopenia And Limbic Encephalopathy Complicating Immunotherapy For Clear Cell Endometrial Cancer With Microsatellite Instability-High (MSI-H) |
| Q39615516 | Pembrolizumab (Keytruda) |
| Q92320729 | Pembrolizumab-Induced Seronegative Arthritis and Fasciitis in a Patient with Lung Adenocarcinoma |
| Q90250960 | Peripheral Blood Markers Identify Risk of Immune-Related Toxicity in Advanced Non-Small Cell Lung Cancer Treated with Immune-Checkpoint Inhibitors |
| Q54956905 | Peritumoural ground-glass opacity associated with tumour pseudoprogression in a patient with non-small cell lung cancer treated with nivolumab. |
| Q30400366 | Pharmacogenomics of off-target adverse drug reactions |
| Q90028511 | Potential Effect of Immunotherapy Agents on Cognitive Function in Cancer Patients |
| Q38726053 | Practical Immuno-PET Radiotracer Design Considerations for Human Immune Checkpoint Imaging. |
| Q41899044 | Predicting response and toxicity to immune checkpoint inhibitors using routinely available blood and clinical markers. |
| Q59135410 | Predictors of immunotherapy-induced immune-related adverse events |
| Q58754581 | Profile of atezolizumab in the treatment of metastatic non-small-cell lung cancer: patient selection and perspectives |
| Q38881814 | Prospects and progress of atezolizumab in non-small cell lung cancer |
| Q94564651 | Pulmonary Complications Secondary to Immune Checkpoint Inhibitors |
| Q90811958 | Radiothérapie et immunothérapie |
| Q28069323 | Recent Advances in Immunotherapy in Metastatic NSCLC |
| Q92750583 | Retrospective analysis of treatment-naive Slovenian patients with metastatic melanoma treated with pembrolizumab - real-world experience |
| Q39085984 | Review: Immune-Related Adverse Events With Use of Checkpoint Inhibitors for Immunotherapy of Cancer |
| Q90242060 | Rheumatic complications in cancer patients treated with immune checkpoint inhibitors |
| Q90426052 | Risk factors for immune-related adverse events associated with anti-PD-1 pembrolizumab |
| Q51157896 | Risk of cumulative toxicity after complete melanoma response with pembrolizumab. |
| Q92358620 | Risk of immune-related diarrhea with PD-1/PD-L1 inhibitors in different cancer types and treatment regimens |
| Q41934141 | Role of PD-1 in Immunity and Diseases |
| Q55378086 | SOCIETY FOR ENDOCRINOLOGY ENDOCRINE EMERGENCY GUIDANCE: Acute management of the endocrine complications of checkpoint inhibitor therapy. |
| Q55076131 | Safe Administration of Ipilimumab, Pembrolizumab, and Nivolumab in a Patient with Metastatic Melanoma, Psoriasis, and a Previous Guillain-Barré Syndrome. |
| Q89506800 | Safety and Efficacy of Re-treating with Immunotherapy after Immune-Related Adverse Events in Patients with NSCLC |
| Q47119885 | Safety in treatment of hepatocellular carcinoma with immune checkpoint inhibitors as compared to melanoma and non-small cell lung cancer |
| Q52682465 | Second-Line Treatment Landscape for Renal Cell Carcinoma: A Comprehensive Review. |
| Q92632643 | Serious immune-related adverse events in patients with head and neck cancer after checkpoint blockade: Systematic review |
| Q92433793 | Severe arthritis and tenosynovitis caused by immune checkpoint blockade therapy with pembrolizumab (anti-PD-1 antibody) |
| Q47897820 | Severe hepatitis arising from ipilimumab administration, following melanoma treatment with nivolumab |
| Q64230260 | Severe toxicity from checkpoint protein inhibitors: What intensive care physicians need to know? |
| Q91623711 | Sex Differences in Tolerability to Anti-Programmed Cell Death Protein 1 Therapy in Patients with Metastatic Melanoma and Non-Small Cell Lung Cancer: Are We All Equal? |
| Q38996594 | Systematic Pan-Cancer Analysis Reveals Immune Cell Interactions in the Tumor Microenvironment. |
| Q90178689 | Takotsubo cardiomyopathy in cancer patients |
| Q38401891 | The Era of Checkpoint Blockade in Lung Cancer: Taking the Brakes Off the Immune System |
| Q47154926 | The Most Recent Oncologic Emergency: What Emergency Physicians Need to Know About the Potential Complications of Immune Checkpoint Inhibitors |
| Q89810462 | The T cell repertoire in tumors overlaps with pulmonary inflammatory lesions in patients treated with checkpoint inhibitors |
| Q90446250 | The mechanisms of acute interstitial nephritis in the era of immune checkpoint inhibitors in melanoma |
| Q38788124 | The safety of nivolumab for the treatment of advanced non-small cell lung cancer |
| Q50921394 | The second wave of immune checkpoint inhibitor tsunami: advance, challenges and perspectives. |
| Q92890914 | The yin and yang of co-inhibitory receptors: toward anti-tumor immunity without autoimmunity |
| Q56887933 | Thyroid disorders induced by checkpoint inhibitors |
| Q47327506 | Tocilizumab for the management of immune mediated adverse events secondary to PD-1 blockade |
| Q58092594 | Toxic Side Effects of Targeted Therapies and Immunotherapies Affecting the Skin, Oral Mucosa, Hair, and Nails |
| Q92876446 | Treatment Outcomes of Immune-Related Cutaneous Adverse Events |
| Q49572087 | Treatment Related Adverse Events Predict Improved Clinical Outcome in NSCLC Patients on KEYNOTE-001 at a Single Center |
| Q58768754 | Treatment of mycophenolate-resistant immune-related organizing pneumonia with infliximab |
| Q52681592 | Tumor Immunology and Immunotherapy for Head and Neck Squamous Cell Carcinoma. |
| Q91651899 | Worsening and newly diagnosed paraneoplastic syndromes following anti-PD-1 or anti-PD-L1 immunotherapies, a descriptive study |
| Q89862626 | [Chinese Experts Consensus on Immune Checkpoint Inhibitors for Non-small Cell Lung Cancer (2019 version)] |
| Q52426571 | [First use of CRISPR for gene therapy]. |
| Q92237309 | [Progress of Steroids Effect on Efficacy of Immune Checkpoint Inhibitors] |
| Q92728812 | [Progress on PD-1/PD-L1 Checkpoint Inhibitors in Lung Cancer] |
| Q64232638 | ePROs in the follow-up of cancer patients treated with immune checkpoint inhibitors: a retrospective study |